Navigation Links
United Therapeutics Corporation Completes Enrollment of FREEDOM-C(2) Trial
Date:3/21/2011

SILVER SPRING, Md., March 21, 2011 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that enrollment in its FREEDOM-C(2) registration trial was completed on March 18, 2011.

FREEDOM-C(2) is a 16-week, multi-center, international, double-blind, randomized, placebo-controlled study of a sustained release oral formulation of treprostinil diethanolamine (UT-15C) in pulmonary arterial hypertension (PAH) patients receiving an endothelin receptor antagonist and/or a phosphodiesterase-5 inhibitor.

The FREEDOM-C(2) study randomized 313 patients, compared to a target enrollment of 300 patients.  The primary endpoint of the trial is change in six-minute walk distance at Week 16 in the treatment group compared to placebo.

"Completion of enrollment in FREEDOM-C(2) represents another significant milestone toward the planned filing of the UT-15C NDA," said Roger Jeffs, Ph.D., President and Chief Operating Officer of United Therapeutics. "This study, if successful, will support the use of UT-15C as add-on therapy to currently approved oral medications, and should significantly enhance early adoption and market uptake of UT-15C."

United Therapeutics expects to unblind and announce preliminary analysis of the FREEDOM-C(2) study results in September 2011.

About United Therapeutics Corporation

United Therapeutics is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. [uthr-g]

Forward-looking Statements

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, our expectations on the timing of unblinding of the FREEDOM-C(2) study, our belief that the FREEDOM-C(2) study unblinding will bring us closer to the goal of achieving an approved oral prostacyclin therapy for PAH and our expectations that the study will enhance early adoption and market uptake of UT-15C.  These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results.  Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and current reports on Form 8-K.  We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of March 21, 2011, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.


'/>"/>
SOURCE United Therapeutics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results
2. United Therapeutics Corporation to Announce Fourth Quarter and Annual 2010 Financial Results Before Market Open on Tuesday, February 15, 2011
3. United Therapeutics Corporation Reports Third Quarter 2010 Financial Results
4. United Therapeutics Corporation to Announce Third Quarter 2010 Financial Results Before Market Open on Thursday, October 28, 2010
5. Sangart, Inc. Receives $1.1 Million Grant Award from the United States Department of Defense for Further Development of MP4 Molecule in Trauma
6. United Therapeutics Corporation to Announce Second Quarter 2010 Financial Results Before Market Open on Wednesday, July 28, 2010
7. Report Details How States Respond to Citizens United Decision
8. United Nations' World Population Day Calls Attention to Key Global Issues
9. United Therapeutics and Lees Pharmaceutical Sign Remodulin Distribution Agreement for China
10. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
11. Abt Bio-Pharma Solutions, Inc. Acquired by United BioSource Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... USDM Life Sciences ... the life sciences and healthcare industries, announces a presentation by Subbu Viswanathan and ... presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present a revolutionary approach ...
(Date:10/9/2017)... 9, 2017  BioTech Holdings announced today identification ... its ProCell stem cell therapy prevents limb loss ... Company, demonstrated that treatment with ProCell resulted in ... as compared to standard bone marrow stem cell ... in reduction of therapeutic effect.  ...
(Date:10/9/2017)... ... October 09, 2017 , ... At its national board meeting ... a professor in Harvard University’s Departments of Physics and Astronomy, has been selected for ... of the winning team for the 2015 Breakthrough Prize in Fundamental physics for the ...
(Date:10/9/2017)... Texas (PRWEB) , ... October ... ... study published on October 5, 2017, in the medical journal, Epilepsia, Brain ... with the gold standard, video EEG, in detecting generalized tonic-clonic seizures (GTCS) ...
Breaking Biology Technology:
(Date:4/5/2017)... April 5, 2017 Today HYPR Corp. ... the server component of the HYPR platform is officially ... the end-to-end security architecture that empowers biometric authentication across ... has already secured over 15 million users across the ... of connected home product suites and physical access represent ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
(Date:3/30/2017)... YORK , March 30, 2017 Trends, ... type (physiological and behavioral), by technology (fingerprint, AFIS, iris ... voice recognition, and others), by end use industry (government ... and immigration, financial and banking, and others), and by ... Europe , Asia Pacific , ...
Breaking Biology News(10 mins):